Citizens Financial Group Inc RI Buys 961 Shares of Insulet Co. (NASDAQ:PODD)

Citizens Financial Group Inc RI increased its stake in Insulet Co. (NASDAQ:PODD) by 4,004.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 985 shares of the medical instruments supplier’s stock after acquiring an additional 961 shares during the period. Citizens Financial Group Inc RI’s holdings in Insulet were worth $163,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PODD. Private Capital Group LLC raised its position in Insulet by 49.6% during the 1st quarter. Private Capital Group LLC now owns 169 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 56 shares during the last quarter. Huntington National Bank raised its position in Insulet by 65.9% during the 4th quarter. Huntington National Bank now owns 146 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 58 shares during the last quarter. ProShare Advisors LLC raised its position in Insulet by 4.2% during the 4th quarter. ProShare Advisors LLC now owns 1,478 shares of the medical instruments supplier’s stock valued at $253,000 after purchasing an additional 60 shares during the last quarter. Piedmont Investment Advisors Inc. raised its position in Insulet by 1.7% during the 4th quarter. Piedmont Investment Advisors Inc. now owns 4,462 shares of the medical instruments supplier’s stock valued at $764,000 after purchasing an additional 73 shares during the last quarter. Finally, Eaton Vance Management raised its position in Insulet by 1.8% during the 4th quarter. Eaton Vance Management now owns 4,245 shares of the medical instruments supplier’s stock valued at $727,000 after purchasing an additional 77 shares during the last quarter.

Insulet stock opened at $192.08 on Friday. The company has a quick ratio of 3.42, a current ratio of 4.15 and a debt-to-equity ratio of 15.24. The company has a market capitalization of $12.23 billion, a P/E ratio of 1,211.81 and a beta of 0.93. The stock’s 50 day moving average is $195.38 and its 200 day moving average is $183.90. Insulet Co. has a twelve month low of $103.26 and a twelve month high of $228.79.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Insulet had a return on equity of 7.66% and a net margin of 0.66%. The company had revenue of $198.00 million during the quarter, compared to analysts’ expectations of $189.61 million. During the same quarter in the previous year, the company earned $0.07 EPS. The business’s quarterly revenue was up 23.8% on a year-over-year basis. As a group, equities analysts expect that Insulet Co. will post 0.16 EPS for the current year.

In other Insulet news, SVP Michael P. Spears sold 13,627 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $182.01, for a total transaction of $2,480,250.27. Following the sale, the senior vice president now directly owns 13,560 shares in the company, valued at approximately $2,468,055.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David A. Lemoine sold 1,042 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $177.49, for a total value of $184,944.58. Following the sale, the director now owns 6,948 shares in the company, valued at $1,233,200.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,914 shares of company stock worth $3,101,603. Company insiders own 1.10% of the company’s stock.

A number of research analysts have weighed in on PODD shares. Raymond James upped their target price on Insulet from $205.00 to $220.00 and gave the stock an “outperform” rating in a report on Monday, April 27th. SVB Leerink upped their target price on Insulet from $200.00 to $230.00 and gave the stock a “market perform” rating in a report on Friday, May 8th. BidaskClub upgraded Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. upped their target price on Insulet from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Cfra upped their target price on Insulet from $162.00 to $179.00 and gave the stock a “sell” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $189.00.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Featured Story: How does a security become overbought?

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.